Back to News
Dec 22, 2025 12:30 PM

AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial

On Monday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab).

The trial did not meet the primary endpoint of overall survival (OS) versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

The trial evaluated patients without actionable genomic alterations (AGAs) whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.

Also Read: AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report

The combination of ceralasertib and Imfinzi was generally well tolerated, and the safety profile was consistent with the known profiles of each medicine, with no new safety concerns identified.

Enhertu Secures FDA Breakthrough Designation

Concurrently, AstraZeneca and Daiichi Sankyo Co., Ltd.’s (OTC:DSNKY) Enhertu (trastuzumab deruxtecan) has been ...